IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D2 generation via prostaglandin endoperoxide synthase-2

J Immunol. 1995 Nov 1;155(9):4445-53.

Abstract

Mouse bone marrow-derived mast cells (BMMC) developed with IL-3 generate prostaglandin D2 (PGD2) through the utilization of prostaglandin endoperoxide synthase (PGHS)-1 within several minutes of cross-linking the high affinity Fc receptor for IgE (Fc epsilon RI) by hapten-specific IgE and Ag. We now report that this immediate generation of PGD2 is followed by a 15-fold induction of steady-state transcripts for PGHS-2, with a maximum at 30 min, accompanied by transient expression of PGHS-2 protein. When BMMC were pretreated with c-kit ligand (KL) in combination with IL-10 for 2 h, sensitized with IgE, and activated with Ag, their expression of steady-state transcripts for PGHS-2 increased 111-fold and their expression of PGHS-2 protein was markedly enhanced, with maximal expression at 1 h and 5 h, respectively, after activation. These events were accompanied by PGD2 generation from 1 to 10 h after activation that accounted for approximately 50% of total PGD2 generation. The expression of PGHS-1 protein did not change during this period. The optimal priming interval for the effect of KL plus IL-10 on the IgE-dependent induction of PGHS-2 was 2 h, at which time only this particular cytokine combination acted synergistically with activation by IgE and Ag. In contrast, at 2 days the accessory cytokines that could provide priming with KL included IL-3 and IL-9 in addition to IL-10. Dexamethasone, which inhibited the expression of PGHS-2 but not PGHS-1, and NS-398, a selective inhibitor of PGHS-2, each suppressed the delayed phase but not the immediate phase of PGD2 generation. Conversely, valeryl salicylate, a selective inhibitor of PGHS-1, suppressed the immediate but not the delayed phase of PGD2 generation after cell priming and IgE-dependent activation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Bone Marrow / drug effects
  • Bone Marrow Cells
  • Enzyme Activation / drug effects
  • Enzyme Activation / immunology
  • Immunoglobulin E / physiology*
  • Interleukin-10 / pharmacology
  • Interleukin-3 / pharmacology
  • Interleukin-9 / pharmacology
  • Male
  • Mast Cells / drug effects
  • Mast Cells / enzymology*
  • Mast Cells / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Prostaglandin Antagonists / pharmacology
  • Prostaglandin D2 / biosynthesis*
  • Prostaglandin-Endoperoxide Synthases / biosynthesis*
  • Prostaglandin-Endoperoxide Synthases / physiology
  • Stem Cell Factor / pharmacology

Substances

  • Interleukin-3
  • Interleukin-9
  • Prostaglandin Antagonists
  • Stem Cell Factor
  • Interleukin-10
  • Immunoglobulin E
  • Prostaglandin-Endoperoxide Synthases
  • Prostaglandin D2